| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | CD40 ligand |
| Clinical data | |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| ChemSpider |
|
| KEGG |
|
Frexalimab (SAR441344) is a second-generation monoclonal antibody that inhibits CD40 ligand. It is in development by Sanofi for the treatment of relapsing multiple sclerosis.[1][2][3][4][5][6]
|
Demyelinating diseases of the central nervous system
| |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Signs and symptoms |
| ||||||||
| Investigations and diagnosis |
| ||||||||
| Approved treatment |
| ||||||||
| Other treatments |
| ||||||||
| Demyelinating diseases |
| ||||||||
| Other |
| ||||||||
|
| |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (initiation) |
| ||||||||||||||
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
